\
&
Contact us
This was 1 year ago
LocationRoyal Military Academy
ProgrammesDEFRA Call 2025 – Join us on 22 January 2025!
The DEFRA Call 2025 has been announced, a flagship initiative advancing research and innovation for Belgium’s defence sector. The DEFRA programme (Defence-related Research Action) is a collaborative effort between the Royal Higher Institute for Defence (RHID) and the Federal Science Policy (BELSPO). This synergy aims to enhance Belgium’s technological and military capabilities to meet current and future security challenges.
DEFRA encourages the participation of the Belgian scientific community, fostering close collaboration among universities, research institutes, defence institutions and private companies. By integrating academia, industry and the Ministry of Defence, DEFRA seeks to stimulate applied research in critical areas vital to national security.
Themes of the DEFRA Call 2025
For the 2025 edition, the call will focus on nine strategic themes:
Since its inception, the DEFRA programme has supported numerous innovative projects. Notable examples include research on software cyber resilience (2023), green technologies for military use (2022) and radar and multi-sensor systems (2023).
Don’t miss this opportunity to contribute to the defence and security of our country by participating in the DEFRA Info Day Call 2025 on 22 January 2025, in Brussels at the Royal Military Academy (RMA).
Pre-registration is required before 15 January 2025. No registrations will be accepted after this date.
https://www.belspo.be/SurveyReg/survey.asp?s=202501_DEFRA_Infosession
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.